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Abstract
Human alpha1-acid glycoprotein (AGP) is an acute phase glycoprotein that
has a heterogeneous glycosylation pattern. This pattern can change in certain
diseases, which has resulted in interest in using AGP glycoforms as potential
biomarkers for these diseases. This report describes a method that uses capillary electrophoresis to characterize and analyze AGP glycoforms both in purified samples of AGP and in human serum. This method uses static and dynamic coatings of poly (ethylene oxide) that are applied to a silica capillary
for separation of AGP glycoforms in the reversed-polarity mode of CE and in
the presence of negligible electroosmotic flow. Electrophoretic injection is
performed onto such capillaries by using a stationary stacking interface between the sample and running buffer. In addition, acidic precipitation and desalting are used to allow for the isolation and the analysis of AGP from only
65 μL of serum. Up to eleven AGP glycoform bands can be reproducibly separated by this method, with the difference in migration time between neighboring bands being 12- to almost 60-fold larger than the standard deviation
for the migration time of any given band. A limit of detection down to about
2 nM per glycoform band can be obtained by this method for AGP in serum
based on absorbance detection and without the need for further sample modification or labeling.
Key words: Alpha1-acid glycoprotein, Capillary electrophoresis, Capillary
modification, Electrophoretic injection, Glycoforms, Sample stacking, Serum

Published as Chapter 4 in Terry M. Phillips (ed.), Clinical Applications of Capillary
Electrophoresis: Methods and Protocols, Methods in Molecular Biology, vol. 1972,
DOI: https://doi.org/10.1007/978-1-4939-9213-3_4
Copyright © 2019 Springer Science+Business Media, LLC, part of Springer Nature.
Used by permission.

1

Zhang, Clarke & Hage in Phillips, ed., Clinical Applications (2019)

2

1 Introduction
Human alpha1-acid glycoprotein (AGP) is an acute phase glycoprotein that has a single chain of 183 amino acids and two disulfide bonds [1–3]. AGP is a heavily glycosylated protein. The molecular
weight of AGP is between 41 and 43 kDa, with about 45% of this mass
being due to glycan moieties [1]. As shown in Fig. 1, there are five Nlinked glycosylation sites on AGP, which occur at Asn15, Asn38, Asn54,
Asn75, and Asn85. A heterogeneous mixture of bi-, tri-, or tetra-antennary glycans can be attached to these sites [1]. AGP has a low isoelectric point (2.8 to 3.8) due to the presence of multiple sialic acids
in these glycan chains [1, 2].
Both the concentration and composition of AGP can change with
various diseases and clinical conditions [2, 4–7]. For instance, the normal concentration of AGP in serum ranges from 0.5 to 1.0 mg/mL, or
12 to 24 μM; however, this concentration can increase by up to tenfold in some clinical situations [2]. In addition, alterations in the glycosylation of AGP have been observed. For instance, a decrease in the
degree of glycan branching has been reported in patients with infection and systemic lupus erythematosus (SLE) [4]. An increase in α1–3
fucosylation has been noted in pancreatic cancer [5], and an increase
in levels of AGP sialylation has been seen in ovarian cancer and lymphoma [6, 7]. These changes have made AGP glycoforms and their
related glycosylation patterns of interest as potential biomarkers for
these and other disease states [4–7].

Fig. 1 Examples of complex N-linked glycans that can occur on AGP and the locations of the glycosylation sites on AGP. Abbreviations: GlcNAc N-acetylglucosamine,
Man mannose, Gal galactose, Fuc fucose, NeuAc neuraminic acid (or sialic acid).
The nomenclature used here for the representation of glycans is based on Ref. [24].
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Capillary electrophoresis (CE) is one approach that can be used to
separate and examine the glycoforms of AGP [6, 8–11]. During the
development of these CE methods, various approaches have been
proposed to reduce adsorption of AGP onto the capillary wall and to
modify electroomostic flow for improved precision and better resolution of the glycoform bands. These approaches have included the
use of buffer additives such as putrescine and urea or the use of capillaries that contained a cross-linked coating of dimethylpolysiloxane
[6, 8–10]. In this report, an alternative method was employed in which
static and dynamic coatings of poly (ethylene oxide) (PEO) were applied to a silica capillary. This coating method was used because it has
been shown to allow highly reproducible separations of AGP glycoforms and to provide differences in migration times between neighboring glycoform bands that are 12- to almost 60-fold larger than the
standard deviations of the migration times for these bands [11]. In this
report, these coated capillaries were combined with electrophoretic
injection and UV absorbance detection to examine the major glycoform bands of human AGP.
The use of absorbance detection alone for AGP tends to provide
only modest detection limits in CE due to the short path length of
light in the capillary and the capillary’s small loading capacity [12]. For
instance, a limit of detection of 0.09–0.38 μM is obtained for the glycoform bands of AGP when absorbance detection is employed with
standard hydrodynamic injection [11]. Mass spectrometry is an alternative detection method that has been used with CE, in combination
with immunoaffinity extraction, to examine AGP glycoforms in serum;
however, the cost of the instrumentation and level of training needed
for CE-mass spectrometry has tended to limit its use in routine clinical testing [13–15]. CE with laser-induced fluorescence detection and
fluorescent-labeled AGP can also be used to detect AGP glycoforms
[16], but this approach adds extra steps and time for sample treatment and modifies the structure of AGP. Electrophoretic injection is a
type of electrokinetic injection that can be performed with AGP when
there is a negligible amount of electroosmotic flow present in this system [17]. This situation creates an essentially stationary stacking interface between the sample and running buffer during injection. This
technique can allow for the sensitive detection of AGP (i.e., down to
0.05–0.2 nM) without the need for AGP derivatization and by using
absorbance detection [17].
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Sample pretreatment was further needed to use CE with absorbance detection and electrophoretic injection for the analysis of AGP
in serum (see overall scheme provided in Fig. 2). Multiple chromatographic steps, such as ion-exchange and dye-ligand chromatography,
have been used to isolate AGP from serum or plasma; unfortunately,
this approach generally requires a relatively large sample volume [18,
19]. Immunoaffinity extraction with anti- AGP immobilized support
has been used as well but needs multiple steps for sample loading,
elution, and column regeneration [20]. Acidic precipitation has been
employed for the pretreatment of AGP from plasma but tends to give
a low purity for AGP when compared with immunoaffinity extraction
[20, 21]. The method that is described in this current report combined
acidic precipitation, desalting, and electrokinetic injection for the selective enrichment of AGP from serum using sample volumes of as
little as 65 μL [17].

Fig. 2 General scheme for the sample preparation and CE analysis of glycoform
bands for AGP that has been isolated from serum.
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2 Materials
The water used in the following procedures was prepared with a
Milli-Q water purification system (EMD Millipore Corporation); however, other types of water purification systems can also be used.
2.1 Samples
1. Commercial samples of normal human AGP (≥99% purity, from
pooled human plasma) were obtained from Sigma- Aldrich.
2. Commercial samples of human serum were also obtained from
Sigma-Aldrich, as were made from pooled human male AB plasma
of U.S. origin (sterile-filtered). Each donor that was used to prepare
this commercial sample had been tested by ELISA and found to be
nonreactive for hepatitis B, hepatitis C, and human immunodeficiency virus (see Note 1).
3. The specimens from patients with SLE were de-identified and preexisting serum samples that were supplied by W. Clarke; this work
has been determined to be exempt from IRB review by the Johns
Hopkins School of Medicine, according to the Code of Federal Regulations −45 CFR46.101 b.
2.2 Equipment
1. A Beckman P/ACE MDQ capillary electrophoresis system was used
in this study. Other brands or models of CE systems with equivalent performance can also be used.
2. Spin column desalting column (0.5 mL, 7 kDa cutoff; Thermo Fisher
Scientific).
2.3 Buffers and Solutions
1. 0.5 M Perchloric acid solution, 10 mL: Add 0.429 mL of perchloric
acid (70%) into a 20 mL glass vial and add 9.571 mL water, giving a
final perchloric acid concentration of 0.5 M (see Note 2).
2. 1 M Sodium hydroxide (NaOH) solution, 100 ml: Add 4.0 g of NaOH
into a 150 mL beaker, add 100 mL of water and dissolve the NaOH
through stirring or sonication.
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3. 1 M Hydrochloric acid (HCl) solution, 100 mL: Add 8.333 mL of 37%
(w/w) HCl into a 100 mL volumetric glassware and add water to
the mark.
4. 0.2% (w/v) PEO (viscosity average molecular weight, 8,000,000;
Sigma-Aldrich) prepared in 0.1 M HCl, 100 mL: Add 0.2 g PEO
slowly (see Note 3), with stirring, into 100 mL water that is held in
a container within an 80 °C water bath. Cover the opening of the
flask with an upside-down 100 mL beaker to avoid water evaporation. Stir the solution for 2 h until all of the PEO has dissolved. After this solution has been cooled to room temperature, add 0.833
mL of 37% of HCl to this solution.
5. 20 mM Acetate buffer, pH 4.2, containing 0.05% (w/v) PEO and 0.1%
(w/v) Brij 35, 200 mL:
Solvent A: 0.05% (w/v) PEO and 0.1% (w/v) Brij 35, 300 mL. Add 0.15
g PEO slowly, and with stirring, into a container holding 300 mL water within an 80 °C water bath. Cover the opening of the flask with an
upside-down 100 mL beaker to prevent the evaporation of water. Stir
this solution for an additional 2 h until all of the PEO has dissolved.
After this solution has been cooled to room temperature, add 0.3 g
Brij 35 to the solution with stirring.
Weigh 0.1196 g of sodium acetate trihydrate into a 200 mL beaker.
Add approximately 180 mL of solvent A into this beaker and stir until
all the sodium acetate salt has dissolved. Add 178 μL of glacial acetic
acid to the solution while stirring. Adjust the pH of this solution to 4.2
by adding small amounts of 1 M NaOH or 1 M HCl and while monitoring the pH of solution (see Note 4). Transfer the final solution into
a 200 mL volumetric glassware and add solvent A to fill this flask to
the mark (see Note 5).
2.4 Spin Desalting Column
Remove the spin column’s bottom closure and loosen the cap without fully removing it. A 2.0 mL microcentrifuge tube can be used as
a collection tube with its cap removed. Place the column in this collection tube and centrifuge at 6600 rpm (2000 × g) for 1 min to remove any storage solution that is present in the device. Place a mark
on the side of the spin column where the compacted resin is slanted
upward; this is to make sure the resin is placed the same way after
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every wash or pre-equilibration step. Place the spin column into a
minicentrifuge, with the mark facing outward in all subsequent centrifugation steps. Add 300 μL water (i.e., the solution to be used for
desalting) to the top of the resin bed in the spin column. Centrifuge
at 6600 rpm for 1 min to remove any water. Repeat the addition of
water and this centrifugation process two more times, discarding the
water from the collection tube.
2.5 Fused Silica Capillary
A fused silica capillary with a length of 72 cm should be cut from
capillary tubing with an inner diameter of 50 μm and an outer diameter of 360 μm, as obtained from Polymicro Technologies (Phoenix,
AZ, USA) (see Note 6). This cut can be achieved by using a cleaving
stone. Remove the outer polyimide coating from the capillary in the
desired region of the detection window. This can be done by placing
the capillary on top of the U-shaped opening of an open-ended = in
wrench, with this opening being placed at least 11 cm away from the
near end of the capillary. A lighter can then be used to burn off the
polyimide coating from the capillary over a length of approximately 5
mm (see Note 7). This area should then be gently cleaned by using a
Kimwipe soaked with ethanol. To install the capillary cartridge for the
P/ACE MDQ CE system, insert the long side of the capillary into the
outlet side of cartridge. Carefully pull the capillary from the inlet side
until the detection window appears in the cartridge window. Select
the required aperture clip (size, 100 × 800 μm) (see Note 8), replace
from the back of the cartridge, and use an insertion tool to seat the
O-ring into the front of the aperture (see Note 9). Place seal retainer
clips on both sides of the capillary and snap these retainer clips into
position. Place the cartridge face down against the capillary length
template. Use a cleaving stone to cut and remove the marked portion
of the capillary. Use the rough side of the cleaving stone to burnish
the ends of the capillary until these ends are smooth (see Note 10).
After this step, the final capillary will have an effective length of 50 cm
and a total length of 60.2 cm. Mount the cartridge with the prepared
fused silica capillary into the CE system. To clean the capillary and activate its interior silanol groups, rinse the capillary with 1 M NaOH for
30 min at a pressure of 50 psi, and clean the capillary with water for
10 min at the same pressure [11, 17].
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3 Methods
3.1 Acid Precipitation and Desalting
1. Acid precipitation: Combine a 65 μL portion of serum and 130 μL of
0.5 M perchloric acid in a 0.6 mL microcentrifuge tube and vortex
mix for 20 s. Place the resulting mixture into a minicentrifuge and
allow it to spin at 6600 rpm for 10 min at room temperature. This
step precipitates major proteins from serum while allowing AGP to
be recovered in the supernatant [21].
2. Sample desalting: Place a 130 μL portion of the supernatant from
the acid precipitation step into a spin desalting column. Place the
spin desalting column into a 2.0 mL microcentrifuge tube with the
cap removed as a collection tube and spin the column for 2 min
at 6600 rpm.
This desalting step helps to improve both the loading capacity and extent of zone broadening in the final CE method through
its effect on the relative resistivity (or conductivity) for the sample solution versus the running buffer, as is illustrated in Fig. 3
[17]. The use of both acid precipitation and desalting for sample

Fig. 3 Electropherograms obtained for AGP glycoforms when using human serum
that has been processed by desalting or that was used with no sample pretreatment. This figure is modified with permission from Ref. [17].
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preparation has also been found to result in good recoveries for
AGP glycoforms from serum. For instance, recoveries between
72.3 and 80.9% have been measured when using this pretreatment method to look at AGP glycoform bands from human serum by CE (see Table 1) [17].
3. Sample dilution: Add the filtrate from the previous step to a 20 ml
glass vial that also contains 5 mL of water (see Note 11). This step
is used to reduce the concentration of AGP down to around 1 μg/
mL and generates a relatively large volume of a working sample
solution that can be employed for multiple injections, or reanalysis as needed.
3.2 Capillary Electrophoresis and Electrophoretic Injection
1. CE operating conditions: The following conditions are used for the
final method that is described in this report. The capillary temperature should be maintained at 25 °C during the separation, and
the applied voltage for the separation should be set at −30 kV (see
Note 12). AGP glycoforms can be detected by using their absorbance at 200 nm [11, 17].
Table 1 Characteristics of an electrophoretic injection CE method for AGP glycoform analysis in serum using acid precipitation and desalting for sample pretreatment
Glycoform
band
3
4
5
6
7
8
9

Limit of
detection (nM)a

Precision of
migration timeb

Precision of
peak areab

Recoveryc

2.5
8.2
11.4
8.5
4.8
2.4
2.1

±0.08%
±0.11%
±0.12%
±0.12%
±0.12%
±0.13%
±0.12%

±0.86%
±0.94%
±0.71%
±0.52%
±0.34%
±0.86%
±1.18%

72.3%
80.9%
80.4%
80.5%
80.3%
78.2%
73.6%

Adapted with permission from Ref. [17]
a. The detection limit was calculated by using a signal-to-noise ratio of three, as based on the
standard deviation of the intercept and the slope from a calibration curve for this assay
b. The relative standard deviations listed in these columns are based on measurements made
in triplicate (n = 3) for normal serum that was spiked with 2.5 g/L AGP. The ranges shown
represent ±1 relative standard deviation
c. The recovery was calculated by dividing the slopes of the corresponding calibration curves
that were obtained before and after sample pretreatment with normal serum that had
been spiked with a known amount of AGP
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2. Preparation of static and dynamic coatings of PEO: The capillary is
first cleaned by using a 5 min rinse with 1 M NaOH, followed by a 3
min rinse with water. The coating is applied by rinsing the capillary
for 5 min with 1 M HCl and then rinsing for 5 min with a 0.2% (w/v)
PEO solution that contains 0.1M HCl. The capillary is then rinsed
for 5 min with a running buffer that consists of pH 4.2, 20 mM acetate buffer containing 0.05% (w/v) PEO and 0.1% (w/v) Brij 35. All
of these rinse steps should be performed at an applied pressure of
50 psi, and this rinsing procedure should be repeated before each
CE separation. The effects of changing the buffer pH, capillary coating material or concentration of Brij 35 on the separation of AGP
glycoforms are discussed under Note 13.
3. Electrophoretic injection: Add 1.2 mL of the sample to a buffer vial.
Carry out electrophoretic injection by using a voltage of −5 kV that
is applied for 5 min (see Note 14).
This electrophoretic injection step enables selective injection of
AGP from a sample that has undergone the pretreatment steps described under Subheading 3.1. The selectivity of this approach is
aided by the fact that AGP is one of few proteins that can have a
negative charge at an acidic pH around 4 [22]. The use of an injection time longer than 5 min can result in a higher loading capacity and signal intensity for AGP, as illustrated in Fig. 4a; however, a
lower resolution will also be observed under these conditions due

Fig. 4 Relationship between (a) the total peak area for AGP glycoform bands and
the time used for electrophoretic injection, and (b) the width for the ninth glycoform band for AGP versus the time used for electrophoretic injection. The error bars
represent a range of ±1 S.D. (n = 3) in (a) and a range of ±1 S.D. of the mean (n =
3) in (b). The plots used in this figure were adapted with permission from Ref. [17].
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to the zone broadening that occurs during injection, as shown in
Fig. 4b. In contrast, the use of an injection time that is shorter than
5 min will result in smaller signal intensity with similar broadening
to what is seen at an injection time of 5 min. Based on these trends,
an injection time of 5 min has been determined to provide a good
compromise between detection limits, overall analysis times, and
peak resolution [17].
4. Capillary cleaning and storage: After a single separation or multiple
separations that are carried out as a sequence, the capillary should
be rinsed with 1 M NaOH at 50 psi for 15 min and then rinsed with
water at 50 psi for 10 min. The capillary should be stored in water
when it is not in use (see Note 15).
3.3 Data Analysis
Most of the following procedures for data analysis are specific for
the type of CE system and analysis software that were used in this
study. Equivalent procedures can be employed with alternative CE
systems or software.
1. An electropherogram that has been obtained by the CE system can
be exported as a .cdf file for analysis of its peaks by a program such
as Peakfit version 4.12.
2. Use the “section” option to select a specific region of the electropherogram for closer analysis (i.e., a suggested range of 10–25 min
for most applications of this CE method).
3. To carry out a baseline correction using Peakfit, select the “progressive line” option. This option can be used to correct for artifacts
such as baseline drifting.
4. When using Peakfit for data analysis, select the options “Chromatography” and “Exponentially modified Gaussian or EMG” for peak
type. Select the options “Vary widths,” “Vary shape,” and “Allow negative” for auto scan. Click on the electropherogram to add multiple
simulated peaks and adjust their shape to give an approximate fit
to the electropherogram.
5. When using Peakfit, select and click the button that says “Fast peak
fit with numerical update” until the best fit is obtained. Next, select
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and click the options “Review fit” and “Numeric” to acquire the
measured parameters for each individual peak or band. To obtain
more parameters for the simulated peaks, select “Options” to add
in additional factors such as “Chromatography analysis.”
3.4 Analysis of AGP Glycoform Bands in Serum Samples
1. The electropherograms in Fig. 5a show some typical results that
were obtained by the overall sample pretreatment and CE method
for normal and SLE serum samples. The migration times and peak
areas of the individual glycoform bands in these electropherograms
were obtained by following the data analysis procedures that were
described under Subheading 3.3.
2. The total peak area for AGP in the electropherogram can be obtained in this particular method by using a summation of the peak
areas for the individual glycoform bands (see Note 16). A correction
of the peak areas based on their apparent mobilities, as is common
in other CE methods, is not needed in this approach with negligible
electroosmosis because the bias of peak area in detection due to
differential mobility has already been corrected during the electrophoretic injection process [17]. The relative peak area due to each

Fig. 5 (a) Electropherograms obtained for AGP from SLE serum or pooled normal
serum, in which the mobility marker (Lucifer yellow CH, LyCH) was introduced by
hydrodynamic injection after sample injection. (b) Glycoform patterns obtained for
AGP from SLE serum or pooled normal serum by this CE method; the error bars
shown for the migration times and % peak areas represent ±1 S.D. of the mean (n
= 3). These plots are reproduced with permission from Ref. [17].
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individual band can be found by dividing the separate band/peak
areas by the total peak band/peak for AGP.
3. The glycoform band distribution pattern for AGP can be visualized
by making a plot of the percentage peak area for each glycoform
band (placed on the y-axis) versus the migration time of each individual band (on the x-axis) [17]. Examples of such plots are shown
in Fig. 5b.
4. This sample preparation and CE method has been found to have a
limit of detection ranging from 2.1 to 11.3 nM for the major glycoform bands of AGP in human serum [17]. These limits of detection
are approximately 3000-fold lower than the concentration of AGP
that is normally observed in human serum and allow this method
to be used with only 65 μl of serum without the need for any sample labeling [17].
5. The precision of the migration times for the AGP glycoform bands
is between ±0.08 and 0.13%; the precisions for the peak areas are
between ±0.34 and 1.18% when using an internal standard to correct the peak areas for their variations in loading capacity during
the injection process (see Table 1). This reproducible separation allows the direct use of migration times to identify and distinguish
between AGP glycoform bands in this method [17].

4 Notes
1. Any work with human samples such as serum that may contain bloodborne pathogens should be handled according to appropriate biosafety
protocols and in BSL-2 facilities.
2. Use appropriate chemical hazard precautions and facilities when handling
perchloric acid [23].
3. This step is to avoid the formation of aggregates of PEO, which will be
difficult to dissolve.
4. Be sure to calibrate the pH meter before use, as the separation of AGP
glycoforms by CE can be sensitive to a small change in the pH of the running buffer [11].
5. Do not filter this buffer solution because the PEO may not be able to pass
through the filter (e.g., one using a 0.2 μm pore size membrane).
6. The protocol described in this report has been developed for these particular capillary dimensions. The use of other capillary dimensions will
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affect the resolution, overall analysis time, and peak broadening that are
obtained in the final method, and will require further optimization of parameters such as the applied voltage and capillary pretreatment/rinsing
protocol, among other factors.
7. Extra care needs to be taken when handling a capillary that contains a
region without a polyimide coating because the exposed region of this
capillary can be quite brittle.
8. Make sure the O-ring has been removed from the aperture clip before
installing the aperture clip. A preinstalled O-ring inside the aperture clip
can crack the capillary when you are installing the aperture clip.
9. Make sure the O-ring lays flat after its installation. An improper orientation of the O-ring will block the light path and create resistance when
connecting the optical fiber with the aperture clip.
10. A magnifying lens can be used to inspect the end of capillary. A rough
end on the capillary will result in a tailing effect for all the AGP glycoform
bands in the final method and should be avoided.
11. The remaining contents of the serum sample are diluted by 115.4-fold
as a result of the overall pretreatment procedure.
12. An applied voltage of −30 kV is the highest setting that is available in
the CE system that was used in this work. A lower applied voltage can be
used but will generate a smaller electric field, leading to reduced migration speeds and longer analysis times. The peaks or bands will also appear broader in the time domain under lower voltage conditions.
13. Several other pH conditions have been evaluated for use with this
method. When using a pH range of 3.8 to 5.0 for the running buffer, it
was found that the best compromise between resolution and peak broadening was obtained at pH 4.2 [11]. As is shown in Fig. 6, an increase in
resolution was observed for AGP glycoform bands in going from pH 5.0
to 4.2; however, the zone broadening increased and led to a reduction in
resolution when going from pH 4.2 to 3.8.
The effect of changing the concentration of Brij 35 as a buffer additive
has been evaluated over the range of 0 to 0.5% (w/v). It was found that
the use of 0.1% Brij 35 gave the best resolution for the glycoform bands,
as is illustrated in Fig. 7 [11].
Table 2 compares the results that were obtained when using various
types of coatings for the CE capillary. It was found that the use of PEO as
both a static and dynamic coating reagent resulted in the greatest reduction of electroosmotic flow and the shortest overall analysis time when
compared to capillary coatings based on poly(vinyl alcohol) (or PVA) or
dextran for the separation of AGP glycoforms [11].
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Fig. 6 Electropherograms showing the effect of pH on the separation and resolution of AGP glycoform bands by CE. This figure is reproduced with permission from
Ref. [11].

Fig. 7 Average resolution obtained for AGP glycoform bands by CE as a function
of the concentration of Brij 35 that was placed into the running buffer. This figure
was reproduced with permission from Ref. [11]. The error bars represent a range of
±1 S.D. (n = 3).
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Table 2 Effect on electroosmotic flow when using various modification agents and methods
to treat fused silica capillariesa

Modification agent and method

Mobility due to
electroosmotic flow,
μosm (× 10−3cm2min−1V−1)

Poly(vinyl alcohol) (or PVA) – Permanent coating
PVA – Permanent plus dynamic coating
PVA – Static coating
PVA – Static plus dynamic coating
Poly (ethylene oxide) (or PEO) – Static coating
PEO – Static plus dynamic coating
Dextran – Static coating
Dextran – Static plus dynamic coating

7.05 (±0.02)
7.09 (±0.23)
11.04 (±0.27)
9.85 (±0.06)
1.83 (±0.01)
0.222 (±0.002)
9.76 (±0.01)
9.89 (±0.10)

Reduction in
electroosmotic flow
(%)
65.8 (±1.4)
66.8 (±1.8)
48.0 (±2.6)
52.3 (±2.0)
91.1 (±0.4)
98.9 (±0.1)
52.8 (±2.0)
51.7 (±2.1)

Reproduced with permission from Ref. [11]
a. The mobility due to electroosmotic flow for a fused silica capillary was 20.66 (±0.87) ×
10−3 cm2 min−1 V−1. The electroosmotic flow was measured in pH 4.2, 20 mM acetate buffer with a sample containing 1.0 g/L thiourea in water. All of the results represent the average of three trials, where the number in parentheses corresponds to a range of ±1 S.D

14. The “inject” event during the method program has a time limit of up to
99 s. For the particular CE system that was employed in this study, a “separate” event can be used instead for sample injection during the method
program for applying a voltage for 5 min. The sample can be added to a
2.0 mL vial and placed into the buffer tray to use this event.
Every sample vial is only used for injection once in this approach because electrophoretic injection will deplete AGP from the sample vial
without depleting the buffer or solvent. This means the concentration
of AGP in the original sample vial will be reduced after even a single injection step.
15. This procedure should be performed right away after a separation sequence or multiple separations to avoid the permanent adsorption of
serum proteins to the inner surface of the capillary, as may occur if this
capillary has been left unrinsed for a long time.
16. The peak area obtained by this method represents the true value without bias due to differences in the mobilities of the separate AGP glycoform bands [17]. When two analytes with the same quantity are injected
by this approach, the analyte peak that has the longer migration time will
have a larger area than the peak for the second analyte with the shorter
migration time. This bias effect is automatically corrected during electrophoretic injection because a smaller amount is injected for an analyte
with a smaller apparent mobility. More details on the theory of this approach can be found in Ref. [17].
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